Key Findings from Treatment Algorithms: Major Depressive Disorder
Decision Resources, Inc, December 2011, Pages: 35
For the first-line treatment of major depressive disorder (MDD), physicians most commonly prescribe a selective serotonin reuptake inhibitor (SSRI) or selective serotonin and norepinephrine reuptake inhibitor (SNRI) within one year of diagnosis. Most of the drugs in these classes are available as low-cost generics. Our analysis indicates that the patient shares of more recently launched antidepressants, including Pfizer’s Pristiq, Sanofi’s Aplenzin, and Angelini Labopharm’s Oleptro, are much lower than those of generic products in first- and even second-line therapy—demonstrating the increasing difficulty that new products are having penetrating the MDD market.
As a result of this environment, marketers of MDD products have turned their attention to the treatment-resistant population—i.e., those patients who fail to respond adequately to first-line SSRIs and SNRIs. This patient population is substantial: More than one-third of MDD patients move to a second-line therapy within the first year of diagnosis, and more than one-half of these patients move to a third-line therapy in the first year, a trend that is consistent with the fact that patients are less likely to respond to a drug after each failed treatment attempt.
These data highlight the market potential for therapies approved to treat MDD patients with an inadequate response to SSRIs and/or SNRIs, such as Bristol-Myers Squibb/Otsuka’s atypical antipsychotic Abilify and AstraZeneca’s Seroquel XR, as well as emerging therapies targeting treatment-resistant MDD. Indeed, this study finds that adjunctive MDD therapies are steadily gaining patient share.
1. Background
a) Publication Update
b) Report Contents and Features
c) Current Practice Guidelines
d) Key U.S. Market Events Influencing Treatment Selection
2. Key Findings for Newly Diagnosed Patients
a) Executive Summary
b) Graphical Views
3. Key Findings for Recently Treated Patients
a) Executive Summary
b) Graphical Views
4. Key Findings by Product
a) Lexapro
b) Cymbalta
c) Pristiq
d) Abilify
e) Seroquel XR
5. Appendix: Methodology
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
